Thrombocytopenia in pregnancy

Platelets

Volumn , Issue , 2007, Pages 925-942

  McCrae, Keith R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884766566     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50813-2     Document Type: Chapter

References (189)

1. McCrae K.R., Bussel J.B., Mannucci P.M., et al. Platelets: An update on diagnosis and management of thrombocytopenic disorders. Hematology (Am Soc Hematol Educ Program) 2001, 282-305.
2. McCrae K.R., Cines D.B. Thrombotic microangiopathy during pregnancy. Sem Hematol 1997, 34:48-158.
3. McMinn J.R., George J.N. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apheresis 2001, 16:202-209.
4. Crowther M.A., Burrows R.F., Ginsberg J., et al. Thrombocytopenia in pregnancy: Diagnosis, pathogenesis and managment. Blood Rev 1996, 10:8-18.
5. Kelton J.G. Idiopathic thrombocytopenic purpura complicating pregnancy. Blood Rev 2002, 16:43-46.
6. Provan D., Newland A., Norfolk D., et al. Guidelines for the investigation and managment of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003, 120:574-596.
7. Shehata N., Burrows R.F., Kelton J.G. Gestational thrombocytopenia. Clin Obstet Gynecol 1999, 42:327-334.
8. Burrows R.F., Kelton J.G. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med 1988, 319:142-145.
9. McCrae K.R., Samuels P., Schreiber A.D. Pregnancy-associated thrombocytopenia: Pathogenesis and management. Blood 1992, 80:2697-2714.
10. Burrows R.F., Kelton J.G. Thrombocytopenia at delivery: A prospective survey of 6715 deliveries. Am J Obstet Gynecol 1990, 162:731-734.
11. Matthews J.H., Benjamin S., Gill D.S., et al. Pregnancy-associated thrombocytopenia: Definition, incidence and natural history. Acta Haemat 1990, 84:24-29.
12. Boehlen F., Hohlfeld H., Extermann P., et al. Platelet count at term pregnancy: A reappraisal of the threshold. Obstet Gynecol 2000, 95:29-33.
13. Sainio S., Kekomäki R., Riikonon S., et al. Maternal thrombocytopenia at term: A population-based study. Acta Obstet Gynecol Scand 2000, 79:744-749.
14. Burrows R.F., Kelton J.G. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993, 329:1463-1466.
15. Letsky E.A., Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Br J Haematol 1996, 95:21-36.
16. Ruggeri M., Schiavotto C., Castaman G., et al. Gestational thrombocytopenia: A prospective study. Haematologica 1997, 82:341-342.
17. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 2002, 346:13-995.
18. Provan D., Newland A. Idiopathic thrombocytopenic purpura in adults. J Ped Hematol Oncol 2003, 25:S34-S38. (suppl 1.
19. Harrington W.J., Minnich V., Hollingsworth J.W., et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951, 38:1-8.
20. Cines D.B., McMillan R. Management of adult idiopathic thrombocytopenic purpura. Ann Rev Med 2005, 56:425-442.
21. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and puri-fied ITP monoclonal autoantibodies inhibit megakaryocytopoiesis. in vitro. Blood 2003, 102:887-895.
22. McMillan R., Wang L., Tomer A., et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004, 103:1364-1369.
23. Gill K.K., Kelton J.G. Management of idiopathic thrombocytopenic purpura in pregnancy. Sem Hematol 2000, 37:275-283.
24. Karim R., Sacher R.A. Thrombocytopenia in pregnancy. Curr Hematol Rep 2004, 3:128-133.
25. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003, 120:574-596.
26. Webert K.E., Mittal R., Siguoin C., et al. A retrospective 11-year analysis of obstetric patients with idiopathic thromobocytopenic purpura. Blood 2003, 102:4306-4311.
27. Samuels P., Main E.K., Tomaski A., et al. Abnormalities in platelet antiglobulin tests in preeclamptic mothers and their neonates. Am J Obstet Gynecol 1987, 107:109-113.
28. Fujimura K., Harada Y., Fujimoto T., et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Haematol 2002, 75:426-433.
29. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
30. Moeller-Bertram T., Kuczkowski K.M., Benumof J.L. Uneventful epidural labor analgesia in a parturient with immune thrombocytopenic purpura and platelet count of 26,000/mm3 which was unknown preoperatively. J Clin Anesthesiol 2004, 16:51-53.
31. Michel M., Novoa M.V., Bussel J.B. Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol 2003, 123:142-146.
32. Kahn M.J., McCrae K.R. Splenectomy in immune thrombocytopenic purpura: Recent controversies and long-term outcomes. Curr Hematol Rep 2004, 3:317-323.
33. Gottlieb P., Axelsson O., Bakos O., et al. Splenectomy during pregnancy: An option in the treatment of autoimmune thrombocytopenic purpura. Br J Obstet Gynaecol 1999, 106:373-375.
34. Stasi R., Pagano A., Stipa E., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98:952-957.
35. Kimby E., Sverrisdotter E., Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: A case history. Eur J Haematol 2004, 72:292-295.
36. Burrows R.F., Kelton J.G. Pregnancy in patients with idiopathic thrombocytopenic purpura: Assessing the risks for the infant at delivery. Obstet Gynecol Surv 1993, 48:781-788.
37. Kelton J.G. Idiopathic thrombocytopenic purpura complicating pregnancy. Blood Rev 2002, 16:43-46.
38. Godelieve C., Christiaens M.L., Nieuwenhuis H.K., et al. Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol 1997, 90:546-552.
39. Payne S.D., Resnik R., Moore T.R., et al. Maternal characteristics and risk of severe neonatal thrombocytopenia and intracranial hemorrhage in pregnancies complicated by autoimmune thrombocytopenia. Am J Obstet Gynecol 1997, 177:149-155.
40. Peleg D., Hunter S.K. Perinatal management of women with immune thrombocytopenic purpura: Survey of United States perinatologists. Am J Obstet Gynecol 1999, 180:645-650.
41. Zhang J., Meikle S., Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Preg 2003, 203-212.
42. Lain K.Y., Roberts J.M. Contemporary concepts of the pathogenesis and management of preeclampsia. J Am Med Assoc 2002, 287:3183-3186.
43. Duckitt K., Harrington D. Risk factors for preeclampsia at antenatal booking: Systemic review of controlled studies. Br Med J 2005, 330:595-601.
44. Working Group Report on High Blood Pressure in Pregnancy NIH Publication No. 00-3029 2000, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD.
45. Pridjian G., Puschett J.B. Preeclampsia. Part 1: Clinical and pathophysiological considerations. Obstet Gynecol Surv 2002, 57:598-618.
46. American College of Obstet Gynecol. ACOG practice bulletin: Diagnosis and management of preeclampsia in pregnancy. Obstet Gynecol 2002, 99:159-167.
47. Mahmoudi N., Graves S.W., Solomon C.G. Eclampsia: A 13-year experience at a United States tertiary care center. J Womens Health Gender Based Med 1999, 8:495-500.
48. Esplin M.S., Fausett M.B., Fraser A., et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001, 344:867-872.
49. Mills J.L., Klebanoff M.A., Graubard B.I., et al. Barrier contraceptive methods and preeclampsia. J Am Med Assoc 1991, 265:70-73.
50. Li D.K., Wi S. Changing paternity and the risk of preeclampsia/eclampsia in the subsequent pregnancy. Am J Epidemiol 2000, 151:57-62.
51. Skjrven R., Wilcox A.J., Lie R.T. The interval between pregnancies and the risk of preeclampsia. N Engl J Med 2002, 346:33-38.
52. Robillard P.Y., Dekker G.A., Hulsey T.C. Revisiting the epidemiological standard of preeclampsia: Primigravidity of primipaternity. Eur J Obstet Gynecol Repro Biol 1999, 84:37-41.
53. Roberts J.M., Cooper D.W. Pathogenesis and genetics of preeclampsia. Lancet 2001, 357:53-56.
54. Pridjian G., Puschett J.B. Preeclampsia. Part 2: Experimental and genetic considerations. Obstet Gynecol Surv 2002, 57:619-640.
55. GOPEC consortium. Disentangling fetal and maternal susceptibility for pre-eclampsia: A British multicenter candidate gene study. Am J Human Genet 2005, 77:127-131.
56. Saftlas A.F., Beydoun H., Triche E. Immunogenetic determinants of preeclampsia and related pregnancy disorders: A systematic review. Obstet Gynecol 2005, 106:162-172.
57. Alsulyman O.M., Castro M.A., Zuckerman E., et al. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gynecol 1996, 88:644-646.
58. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arth Rheum 1999, 42:1309-1311.
59. Shehata H.A., Nelson-Piercy C., Khamashta M.A. Management of pregnancy in the antiphospholipid syndrome. Rheum Dis Clin NA 2001, 27:643-649.
60. Dekker G.A., deVries J.I., Doelitzsch P.M., et al. Underlying disorders associated with severe, early onset preeclampsia. Am J Obstet Gynecol 1995, 173:1042-1048.
61. Dizon-Townson D.S., Nelson L.M., Easton K., et al. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996, 175:902-905.
62. Grandone E., Margaglione M., Colaizzo D., et al. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997, 77:1052-1054.
63. Kupferminc M.J., Eldor A., Steinman M., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999, 1999:340-349.
64. D'Elia A.V., Driul L., Giacomello R., et al. Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia. Gynecol Obstet Invest 2002, 53:84-87.
65. Anonymous. Is there an increased maternal-infant prevalence of factor V Leiden in association with severe preeclampsia? Br J Obstet Gynaecol 109 191-196.
66. Livingston J.C., Barton J.R., Park V., et al. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001, 185:153-157.
67. Alfirevic Z., Roberts D., Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Repro Biol 2002, 101:6-14.
68. Stanley-Christian H., Ghidini A., Sacher R., et al. Fetal genotype for specific thrombophilias is not associated with severe preeclampsia. J Soc Gynecol Invest 2005, 12:198-201.
69. Witsenburg C.P.J., Rosendall F.R., Middeldorp J.M., et al. Factor VIII levels and the risk of preeclampsia, HELLP syndrome, pregnancy related hypertension and severe intrauterine growth retardation. Thromb Res 2005, 115:382-392.
70. Goldman-Wohl D., Yagel S. Regulation of trophoblast invasion: From normal implantation to preeclampsia. Mol Cell Endocrinol 2002, 187:233-238.
71. Brosens I.O. The utero-placental vessels at term -the distribution and extent of physiological changes. Troph Res 1988, 3:61-67.
72. Khong T.Y., De Wolf F., Robertson W.B., et al. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small for gestational age infants. Am J Obstet Gynecol 1987, 157:360-363.
73. Zhou Y., Damsky C.H., Chiu K., et al. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993, 91:950-960.
74. Zhou Y., Damsky C.H., Fisher S.J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. J Clin Invest 1997, 99:2152-2164.
75. Zhou Y., Fisher S.J., Janatpour M., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. J Clin Invest 1997, 99:2139-2151.
76. Graham C.H., McCrae K.R. Expression of gelatinase and plasminogen activator activity by trophoblast cells isolated from the placentae of normal and preeclamptic women. Am J Obstet Gynecol 1996, 175:555-562.
77. Tsatsiris V., Goffinm F., Munuat C., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endo Metab 2003, 88:5555-5563.
78. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
79. Soleymanlou N., Jurisica I., Nevo O., et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005, 90:4299-4308.
80. Taylor R.N., Varma M., Teng N.N.H., et al. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990, 71:1675-1677.
81. Nova A., Sibai B.M., Barton J.R., et al. Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol 1991, 165:724-727.
82. Dekker G.A., Kraayenbrink A.A., Zeeman G.G., et al. Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe preeclampsia. Eur J Obstet Gynecol Repro Biol 1991, 40:215-220.
83. Myatt L., Cui X. Oxidative stress in the placenta. Histochem Cell Biol 2004, 122:369-382.
84. McCrae K.R. Thrombocytopenia in pregnancy: Differential diagnosis, pathogenesis and management. Blood Rev 2003, 17:7-14.
85. deBoer K., ten Cate J.W., Sturk A., et al. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989, 160:95-100.
86. Brenner B., Zwang E., Bronshtein M., et al. Von Willebrand factor multimer patterns in pregnancy-induced hypertension. Thromb Haemost 1989, 62:715-717.
87. Thorp J.M., White G.C., Moake J.L., et al. Von Willebrand factor multimeric levels and patterns in patients with severe preeclampsia. Obstet Gynecol 1990, 75:163-167.
88. Lockwood C.J., Peters J.H. Increased plasma levels of ED1+ cellular fibronectin precede the clinical signs of preeclampsia. Am J Obstet Gynecol 1990, 162:358-362.
89. Redman C.W.G., Beilin L.J., Denson K.W.E., et al. Factor VIII consumption in pre-eclampsia. Lancet, ii 1977, 1249-1252.
90. Curtin W.M., Weinstein L. A review of the HELLP syndrome. J Perinatol 1999, 19:138-143.
91. O'Brien J.M., Barton J.R. Controversies with the diagnosis and management of HELLP syndrome. Clin Obstet Gynecol 2005, 48:460-477.
92. Barton J.R., Sibai B.M. Diagnosis and management of hemolysis, elevated liver enzymes and low platelets syndrome. Clin Perinatol 2004, 31:807-833.
93. Sibai B.M. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): Much ado about nothing?. Am J Obstet Gynecol 1990, 162:311-316.
94. Martin J.N., Blake P.G., Lowry S.L., et al. Pregnancy complicated by preeclampsia with the syndrome of hemolysis, elevated liver enzymes, and low platelet counts: How rapid is postpartum recovery. Obstet Gynecol 1990, 76:737-741.
95. Rath W., Faridi A., Dudenhausen J.W. HELLP syndrome. J Perinatal Med 2000, 28:249-260.
96. McMahon L.P., Smith J. The HELLP syndrome at 16 weeks gestation: Possible association with the antiphospholipid syndrome. Aust NZJ Obstet Gynaecol 1997, 37:313-314.
97. Haram K., Trovik J., Sanset P.M., et al. Severe syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in the 18th week of pregnancy associated with the antiphospholipid-antibody syndrome. Acta Obstet Gynecol Scand 2003, 82:679-680.
98. Li Thi Thoung D., Tieulie N., Costedoat N., et al. The HELLP syndrome in the antiphospholipid syndrome: Retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005, 64:273-278.
99. Nagayama K., Izumi N., Miyasaka Y., et al. Hemolysis, elevated liver enzymes, and low platelets syndrome associated with primary anti-phospholipid antibody syndrome. Intern Med 1997, 36:661-667.
100. Magann E.F., Martin J.R. Twelve steps to optimal management of HELLP syndrome. Clin Obstet Gynecol 1999, 42:532-550.
101. Sibai B.M. Diagnosis, controversies and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004, 103:981-991.
102. Murphy M.A., Ayazifar M. Permanent visual defects secondary to the HELLP syndrome. J Neuro-Opthalmol 2005, 25:122-127.
103. Rinehart B.K., Terrone D.A., May W.L., et al. Change in platelet count predicts eventual maternal outcome with syndrome of hemolysis, elevated liver enzymes and low platelet count. J Mat Fet Med 2001, 10:28-34.
104. Martin J.N., Blake P.G., Perry K.G., et al. The natural history of HELLP syndrome: Patterns of disease progression and regression. Am J Obstet Gynecol 1991, 164:1500-1513.
105. Faridi A., Heyl W., Rath W. Preliminary results of the International HELLP-Multicenter-Study. Int J Gynaecol Obstet 2000, 69:279-280.
106. Sibai B.M., Taslimi M.M., El-Nazer A., et al. Maternal-perinatal outome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986, 155:501-509.
107. Schwartz M.L., Brenner W.E. The obfuscation of eclampsia by thrombotic thrombocytopenic purpura. Am J Obstet Gynecol 1978, 131:10-18.
108. Coppage K.H., Sibai B.M. Treatment of hypertensive complications of pregnancy. Current Pharm Des 2005, 11:749-757.
109. Visser W., Wallenburg H.C.S. Temporizing management of severe pre-eclampsia with and without the HELLP syndrome. Br J Obstet Gynaecol 1995, 102:111-117.
110. Hogg B., Hauth J.C., Caritis S.N., et al. Safety of labor epidural anesthesia for women with severe hypertensive disease: National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999, 181:1096-1101.
111. Barilleaux P.S., Martin J.N., Klauser C.K., et al. Postpartum intravenous dexamethasone for severely preeclamptic patients without hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome: A randomized trial. Obstet Gynecol 2005, 105:843-848.
112. van Runnard Heimel P.J., Franx A., Schobben A.F.A.M., et al. Corticosteroids, pregnancy, and HELLP syndrome: A review. Obstet Gynecol Surv 2004, 60:57-70.
113. Rose C.H., Thigpen B.D., Bofill J.A., et al. Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Obstet Gynecol 2004, 104:1011-1014.
114. O'Brien J.M., Milligan D.A., Barton J.R. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2000, 183:304-309.
115. Martin J.N., Perry K.G., Blake P.G., et al. Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. Am J Obstet Gynecol 1997, 177:1011-1017.
116. Martin J.N., Files J.C., Blake P.G., et al. Plasma exchange for preeclampsia. I. Postpartum use for persistently severe preeclampsia-eclampsia with HELLP syndrome. Am J Obstet Gynecol 1990, 162:126-137.
117. Martin J.N., Files J.C., Blake P.G., et al. Postpartum plasma exchange for atypical preeclampsiaeclampsia as HELLP (hemolysis, elevated liver enzymes and low platelets syndrome) . Am J Obstet Gynecol 1995, 172:1107-1112.
118. Eser B., Guven M., Unal A., et al. The role of plasma exchange in HELLP syndrome. Clin Applied Thromb/ Hemost 2005, 11:211-217.
119. CLASP Collaborative Group. CLASP: A randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994, 343:619-629.
120. Roberts J.M., Pearson G., Cutler J., et al. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension 2003, 41:437-445.
121. Chappell L.C., Seed P.T., Briley A.L., et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: A randomized trial. Lancet 1999, 354:810-816.
122. Rumbold A., Crowther C.A. Vitamin E supplementation in pregnancy. Cochrane Database Sys Rev 2005, April 18.
123. Miller D.P., Kaye J.A., Ziyadeh N., et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiol 2004, 15:208-215.
124. Torok T.J., Holman R.C., Chorba T.L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States -analysis of national mortality data 1968-1961. Am J Hematol 1995, 5084:90.
125. Ridolfi R.L., Bell W.R. Thrombotic thrombocytopenia purpura: Report of 25 cases and a review of the literature. Medicine 1981, 60:413-428.
126. Vesely S.K., George J.N., Lämmle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003, 102:60-68.
127. Nicol K.K., Shelton B.J., Knovich M.S., et al. Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura. Am J Hematol 2003, 74:170-174.
128. Amarosi E.L., Ultmann J.E. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine 1966, 45:139-159.
129. Nabhan C., Kwaan H.C. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol/Oncol Clin NA 2003, 17:177-199.
130. Thompson C.E., Damon L.E., Ries C.A., et al. Thrombotic microangiopathies in the 1980s: Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992, 80:1890-1895.
131. Cohen J.D., Brechter M.E., Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apheresis 1998, 13:16-19.
132. Berns J.S., Kaplan B.S., Mackow R.C., et al. Inherited hemolytic uremic syndrome in adults. Am J Kidney Dis, XIX 1992, 331-334.
133. Proulx F., Siefdman E.G., Karpman D. Pathogenesis of shiga toxin-associated hemolytic uremic syndrome. Ped Res 2001, 50:163-171.
134. Taylor C.M. Hemolytic uremic syndrome and complement factor H deficiency: Clinical aspects. Sem Thromb Hemost 2001, 27:185-190.
135. McCrae K.R., Sadler J.E., Cines D.B. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Hematology: Basic principles and practice 2005, 2287-2304. Elsevier, Churchill, Livingstone, Philadelphia. R. Hoffman, E.J. Benz, S.J. Shattil, (Eds.).
136. Neild G. The haemolytic uraemic syndrome: A review. Quart J Med 1987, 241:367-376.
137. Schieppati A., Ruggenenti P., Plata Cornejo R., et al. Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. J Am Soc Nephrol 1992, 2:1640-1644.
138. George J.N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000, 96:1223-1229.
139. Esplin M.S., Branch D.W. Diagnosis and management of thrombotic microangiopathies during pregnancy. Clin Obstet Gynecol 1999, 42:360-368.
140. Castella M., Pujol M., Massague I., et al. Thrombotic thrombocytopenic purpura and pregancy: A review of ten cases. Vox Sang 2004, 87:287-290.
141. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339:1578-1584.
142. Tsai H.-M., Lian E.C.Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339:1585-1594.
143. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413:488-494.
144. Bianchi V., Robles R., Alberio L., et al. von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: A severely deficient activity is specifi c for thrombotic thrombocytopenic purpura. Blood 2002, 100:710-713.
145. Tsai H.-M. Is severe deficiency of von Willebrand factor cleaving protease (ADAMTS-13) specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003, 1:625-631.
146. Mannucci P.M., Vanoli M., Forza I., et al. von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis) . Haematologica 2003, 88:914-918.
147. Mannucci P.M., Canciani T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001, 98:2730-2735.
148. Sanchez-Luceros A., Farias C.E., Amaral M.M., et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004, 92:1320-1326.
149. Moake J.L., Byrnes J.J., Troll J.H., et al. Abnormal VIII: von Willebrand factor patterns in the plasma of patients with the hemolytic-uremic syndrome. Blood 1994, 64:592-598.
150. Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002, 347:589-600.
151. Tsai H.-M. Current concepts in thrombotic thrombocytopenic purpura. Ann Rev Med 2005, e-publication.
152. George J.N. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003, 10:339-344.
153. Reiter R.A., Varadi K., Turecek P.L., et al. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005, 93:554-558.
154. Lattuada A., Rossi E., Calzarossa C., et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003, 88:1029-1034.
155. Weiner C.P. Thrombotic microangiopathy in pregnancy and the postpartum period. Sem Hematol 1987, 24:119-129.
156. Proia A., Paesano F., Torcia L., et al. Thrombotic thrombocytopenic purpura and pregnancy: A case report and a review of the literature. Ann Haematol 2002, 81:210-214.
157. Ducloy-Bouthors A.S., Caron C., Subtil D., et al. Thrombotic thrombocytopenic purpura: Medical and biological monitoring of six pregnancies. Eur J Obstet Gynecol Repro Biol 2003, 111:146-152.
158. Clark K. TTP and me. The Practising Midwife 2004, 7:13-17.
159. Sherer D.M., Sanmugarajah J., Dalloul M., et al. Thrombotic thrombocytopenic purpura in a patient with acquired immunodeficiency syndrome at 28 weeks gestation. Am J Perinatol 2005, 22:223-225.
160. Allford S.L., Hunt B.J., Rose P., et al. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology: Guidelines on the diagnosis and management of the thrombotic micro angiopathic haemolytic anaemias. Br J Haematol 2003, 120:556-573.
161. Kwaan H.C., Soff G.A. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Sem Hemato 1997, 34:159-166.
162. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991, 325:393-397.
163. Ruggenenti P., Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996, 56:191-207.
164. Remuzzi G. The hemolytic uremic syndrome. Kidney Int 1995, 47:2-19.
165. Vesely S.K., McMinn J.R., Terrell D.R., et al. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004, 44:1149-1158.
166. Fesenmeir M.F., Coppage K.H., Lambers D.S., et al. Acute fatty liver of pregnancy in three tertiary care centers. Am J Obstet Gynecol 2005, 192:1416-1419.
167. Knox T.A., Olans L.B. Liver disease in pregnancy. N Engl J Med 1996, 335:569-576.
168. Burroughs A.K., Seong N.H., Dojcinov D.M., et al. Idiopathic acute fatty liver of pregnancy in 12 patients. Quart J Med 1982, 51:481-497.
169. Usta I.M., Barton J.R., Amon E.A., et al. Acute fatty liver of pregnancy: An experience in the diagnosis and managment of fourteen cases. Am J Obstet Gynecol 1994, 171:1342-1347.
170. Ibdah J.A., Yang Z., Bennett M.J. Liver disease in pregnancy and fetal fatty acid oxidation defects. Molec Genet Metab 2000, 71:182-187.
171. Ibdah J.A., Bennett M.J., Rinaldo P., et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999, 340:1723-1731.
172. Holub M., Bodamer O.A., Item C., et al. Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome?. Acta Paeds Scand 2005, 94:48-52.
173. Tan A.C., van Krieken J.H., Peters W.H., et al. Acute fatty liver in pregnancy. Netherlands J Med 2002, 60:370-373.
174. Castro M.A., Goodwin T.M., Shaw K.J., et al. Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Am J Obstet Gynecol 1996, 174:211-216.
175. Hepner D.L., Tsen L.C. Severe thrombocytopenia, type 2B von Willebrand disease and pregnancy. Anesthesiol 2004, 101:1465-1467.
176. Casonato A., Sartori M.T., Bertomoro A., et al. Pregnancy-induced worsening of thrombocytopenia in a patient with type IIB von Willebrand's disease. Blood Coag Fibrinol 1991, 2:33-40.
177. Icko M., Sakurama S., Sagawa A., et al. Effect of a factor VIII concentrate on type IIB von Willebrand's disease-associated thrombocytopenia presenting during pregnancy in identical twin mothers. Am J Hematol 1990, 35:26-31.
178. Nardi M., Karpatkin S. Antiidiotype antibody against platelet anti-GPIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients. J Exp Med 2000, 191:2093-2100.
179. Li Z., Nardi M.A., Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1 related immunologic thrombocytopenia. Blood 2005, 106:572-576.
180. Chelucci C., Federico M., Guerriero R., et al. Productive human immunodeficiency virus-1 infection of puri-fied megakaryocytic progenitors/precursors and maturing megakaryocytes. Blood 1999, 91:1225-1234.
181. Diz-Kucukkaya R., Hacehanefioglu A., Yenerel M., et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: A prospective cohort study. Blood 2001, 98:1760-1764.
182. Chakravarty E.F., Colon I., Langen E.S., et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005, 192:1897-1904.
183. Aster R.H. Drug-induced immune cytopenias. Toxicology 2005, 209:149-153.
184. Balduini C.L., Iolascon A., Savoia A. Inherited thrombocytopenias. Haematologica 2002, 87:860-880.
185. Seri M., Cusano R., Gangarossa S., et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes: The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet 2002, 26:103-105.
186. Sibai B.M., Ramadan M.K., Chari R.S., et al. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): Subsequent pregnancy outcome and long term prognosis. Am J Obstet Gynecol 1995, 172:125-129.
187. Sullivan C.A., Magann E.F., Perry K.G., et al. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol 1994, 171:940-943.
188. van Pampus M.G., Wolf H., Mayruu G., et al. Long-term follow-up in patients with a history of (H) ELLP syndrome. Hypertens Preg 2001, 20:15-23.
189. Chames M.C., Haddad B., Barton J.R., et al. Subsequent pregnancy outcome in women with a history of HELLP syndrome at 28 weeks of gestation. Am J Obstet Gynecol 2003, 188:1504-1508.